{"id":332922,"date":"2026-02-12T04:22:18","date_gmt":"2026-02-12T04:22:18","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/332922\/"},"modified":"2026-02-12T04:22:18","modified_gmt":"2026-02-12T04:22:18","slug":"more-than-a-third-of-patients-on-wegovy-pill-are-new-to-glp-1-drugs-study-finds","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/332922\/","title":{"rendered":"More than a third of patients on Wegovy pill are new to GLP-1 drugs, study finds"},"content":{"rendered":"<p>&#13;<\/p>\n<p>Among \u200cearly users \u200bof Novo Nordisk&#8217;s new Wegovy weight-loss \u200cpill, 36% had no prior experience taking a GLP-1 medication, a \u200cnew study from the health data \u200cfirm Truveta found.<\/p>\n<p>Of patients who started a new pill prescription, 21.1% \u2060had previously \u200btaken \u2060the injectable version of Wegovy and \u206015.8% switched from Eli Lilly&#8217;s Zepbound, \u200banother injectable GLP-1 medicine, according to \u2060Truveta data. Truveta reviewed health records \u2060from \u200b8,762 patients with evidence of a prescription for the \u2060new Wegovy pill, which was approved by \u2060the \u2060U.S. Food and Drug Administration on December 22. <\/p>\n<p>&#13;<\/p>\n<p>(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)<\/p>\n<p>&#13;<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; Among \u200cearly users \u200bof Novo Nordisk&#8217;s new Wegovy weight-loss \u200cpill, 36% had no prior experience taking a&hellip;\n","protected":false},"author":2,"featured_media":332923,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[274],"tags":[159050,159053,18,159054,1950,135,19,17,462,159051,159052,5359,46210],"class_list":{"0":"post-332922","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag--u-s-food-and-drug-administration","9":"tag-eoepill","10":"tag-eire","11":"tag-eli-lillys","12":"tag-glp-1","13":"tag-health","14":"tag-ie","15":"tag-ireland","16":"tag-medication","17":"tag-novo-nordisks","18":"tag-truveta","19":"tag-wegovy","20":"tag-zepbound"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/116055752255976561","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/332922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=332922"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/332922\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/332923"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=332922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=332922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=332922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}